Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bulk drug ingredient inspection harmonization likely result of U.S./EU MRA -- FDAer.

This article was originally published in The Tan Sheet

Executive Summary

BULK DRUG INTERNATIONAL INSPECTION STANDARDS LIKELY TO BE ADOPTED as a result of the U.S./European Union Mutual Recognition Agreement, FDA New Jersey District Office Director Douglas Ellsworth told a September Food & Drug Law Institute conference. Active pharmaceutical ingredient manufacturing is not now overseen by a specific authority in any European nation, Ellsworth pointed out. "We've been working with the Pharmaceutical Inspection Convention and others to come up with an international standard for active pharmaceutical ingredients, and I suspect that...will cascade into an international standard and some legislative features perhaps in the European Union," he said.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087654

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel